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ABO hemolytic disease of the newborn (ABO HDN) is the most common maternofetal blood group incompatibility. ABO HDN is restricted almost entirely to Group A or B 
babies born to Group O mothers with immune anti-A or anti-B 
antibodies. Although, HDN has been reported in a baby whose 
mother was Group A with high titres of anti B [1]. Unlike the 
rhesus disease, it is usually a problem of the neonate rather than 
the fetus. ABO-HDN in literature is described as a condition 
having a very low incidence in the population and characterized 
by a benign evolution because of a mild degree of hemolysis [2,3]. 
Anemia is rare with the main clinical problem being jaundice. 
However, severe hemolysis and anemia requiring exchange blood 
transfusion have been reported [4]. Early detection and treatment 
of neonatal hyperbilirubinemia is important in prevention of 
bilirubin-induced encephalopathy in the affected children [5]. 
Routine screening for ABO incompatibility between mother and 
fetus is not performed and according to Han et al., it is not cost-
effective to routinely screen for ABO incompatibility in the Asian 
population [6].
HDN due to rhesus incompatibility is preventable and 
preventable measures are in place in many countries. In contrast, 
there are currently no preventable measures for HDN due to 
ABO incompatibility [7]. Hence, ABO incompatibility is now the 
single most common cause of neonatal jaundice [8]. In this study, 
we aimed at identifying the babies born to the O positive mothers 
at birth and closely monitored these babies to study the clinical 
manifestations and outcome of treatment.
SUBJECTS AND METHODS
A prospective observational cohort study of term neonates born 
to O positive mothers with clinical jaundice of <120 h of age 
was conducted in a sick newborn care unit (SNCU) attached to 
a tertiary level government maternity hospital, Telangana, over 
a period of 6 months from November 2017 to April 2018. Prior 
ethics committee approval was taken and informed consent 
regarding participation in the study was obtained in the regional 
language. All preterm and low birth weight babies, neonate with 
other known causes of jaundice and hemolysis, neonates with 
history of birth asphyxia, sepsis, or congenital anomalies were 
excluded from the study.
The diagnosis of ABO incompatibility was made in the 
presence of indirect hyperbilirubinemia in a newborn infant with 
blood Type A or B and maternal blood type O, in the absence 
of other identified causes. Hemolytic findings due to maternal-
fetal ABO blood group incompatibility were defined as the 
presence of at least two of the followings: (a) Jaundice and or 
anemia of varying degree, (b) circulating nucleated red blood 
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cells, (c) microspherocytosis, or (D) polychromasia on peripheral 
blood smears [7].
All the neonates were examined every 12 h until the first 5 days 
of life for occurrence of jaundice. The babies being discharged 
from the hospital at 48 to 72 h were seen again after 48–72 h of 
discharge. Thorough clinical examination of the baby was done 
to identify pallor, temperature, icterus, hepatosplenomegaly, 
and neurological signs like opisthotonus. Those babies who 
developed clinically significant jaundice, serum bilirubin was 
done by micro method. Direct Coombs test could not be done as 
it is not available at the SNCU. American Academy of Pediatrics 
criteria was used for making decision regarding phototherapy 
or exchange transfusion in these infants [9]. The babies were 
monitored clinically for rebound bilirubin rise within 24 h after 
stopping phototherapy in maternal ward and then discharged.
Statistical analysis
Data were collected on a structured pro forma designed and 
entered into Excel sheet. SPSS version 19 was used for statistical 
analysis. Descriptive statistics such as mean and Chi-square test 
were calculated. p<0.05 was taken as statistically significant.
RESULTS
A total of 100 babies were enrolled in the study based on the 
inclusion and exclusion criteria. Of 100 babies, 25 babies 
were A positive, 47 were B positive, and 28 babies were O 
positive. 28 babies who had no incompatibility, 5 (18%) had 
hyperbilirubinemia requiring phototherapy, the cause of which 
was not known. The mean serum bilirubin level was 12.1 mg/dl 
with maximum level of 18.2 mg/dl. The mean age of developing 
jaundice was 76 h (Table 1).
Rest of the 72 babies who had ABO incompatibility, 52 (72%) 
babies developed hemolysis, for which they were treated with 
phototherapy and 1 baby (1.3%) required exchange transfusion. 
These results show that incompatibility has significantly increased 
the chances of morbidity (Chi-square 22.96, p<0.5). Hence, these 
babies require close follow-up even after discharge.
Of the 72 babies with ABO incompatibility, 37 (51%) were 
male and 35 (49%) were female. The mean birth weight is 2.90 kg. 
31 (43%) were primigravida and 41 (57%) were multigravida 
mothers. 40 (56%) were born out of lower segment cesarian 
section, 32 (44%) were normal vaginal delivery. Of 25 cases with 
A blood group, 20 (80%) required phototherapy. Out of 47 cases 
with Group B blood group, 32 (68%) required phototherapy. 
Only one case required exchange transfusion which had B blood 
group. Mean age at admission is 65.13 h of age (ranging from 
13 h to 120 h). The mean initial level of bilirubin is 16.39 mg/dl. 
The mean reticulocyte count was 13±5.3%. All the cases had 
favorable outcome without any neurological manifestations 
because of close follow-up of all the cases. One case which 
underwent exchange transfusion was also followed and did not 
develop any neurological sequelae due to early management. In 
the present study, of 52 cases requiring phototherapy 25 (48%) 
were male and 27 (52%) were female showing gender does not 
predict hemolysis as p=0.9 which is not statistically significant. 
The demographic details and clinical profile of neonates with A or 
B blood group are shown in Table 1.
In the comparison of newborn infants with blood Group A 
or B, both groups had similar demographic parameters such 
as birth weight, gender, and day of admission. Similarly, there 
were no statistically significant differences in clinical parameters 
such as initial bilirubin levels, hemoglobin levels, duration of 
phototherapy, and outcome.
DISCUSSION
In the present study, there was no significant correlation 
between the serum bilirubin levels and the sex of the newborn, 
and observation was comparable with that of studies by Kumar 
et al. [10], Akgül et al. [11], Shah et al. [12], and Preethi et al. [13]. 
Male newborns had more risk of jaundice, in studies by Singh 
et al. [14], Mantani et al. [15], Sharma et al. [16], and Maisel 
and Watchko [17]. Infants of multigravida and primigravida 
mothers were affected to a similar extent as predicted in a study 
by Dufour and Monoghan [8]. In a study by Akgül et al. [11], the 
mean age on the day of admission to hospital was 4.4±2.4 (0–9) 
Table 1: Demographic and clinical profile of neonates with blood Group A or B
Variables Blood Group A n=25 (%) Blood Group B n=47 (%) p value
Gender (M/F) 12 (48)/13 (52) 25 (53)/22 (47) 0.67
Mean birth weight (kg) 2.88±0.3 2.90±0.34 -
Parity (primi/multi) 10 (40)/15 (60) 21 (45)/26 (55) 0.7
Mean age at admission (h) 73.15±31.7 60.37±29.4 -
Presence of hemolysis 20 (80) 32 (68) 0.28
Initial bilirubin (mg/dl) 16.46±2.4 16.35±4.3 -
Jaundice in first 24 h 1 (4) 3 (6.3) 0.6
Anemia (Hb <13 g/dl) 4 (16) 7 (14.8) 0.9
Duration of phototherapy (h) 53.7±10.3 (Range: 38–96) 54.5±9.8 (Range: 48–110) 0.4
Exchange transfusion 0 (0) 1 (2.1) -
Intravenous immunoglobulin given 0 (0) 0 (0)
Discharged successfully 25 (100) 47 (100) -
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days while it was 3.04 days in the present study which may be 
due to early recognition of cases. The mean initial bilirubin was 
19.9±5.7 (7.1–41.3) mg/dl in a study conducted by Kattimani 
and Ushakiran [18] while it was 16.39 (8.6–24.5) mg/dl in 
the present study. In the present study, mean age at admission 
was 65.13 h (range: 13–120 h) which is comparable to the 
mean age of 2.9±0.89 days in a study conducted by Kattimani 
and Ushakiran [18]. In the present study, 72% babies required 
phototherapy and 1.3% required exchange transfusion while in a 
study by Bhat and Kumar [19], phototherapy was required in 46% 
of the cases and none required exchange transfusion.
We found that out of 72 babies developing hemolysis 
47 (65%) were of B blood group and 25 (35%) were of A blood 
group. Similar B blood group preponderance was found by 
Kattimani and Ushakiran [18]. As “B” blood group is the second 
most common blood group in India after “O” blood group, we can 
explain the higher incidence of OB incompatibility in our set up. 
In the present study, there was no significant difference in severity 
and outcome in both O-A and O-B incompatibility; although 
O-B incompatibility was more. Similar observations were made 
by Kumar et al. [10], Ella et al. [20], and Bhat and Kumar [19]. 
However, McDonnell et al. [21] and Stiller et al. [22] concluded 
that ABO incompatibility might cause more fetal anemia in patient 
with type B blood group. The present study was limited to only 
symptomatic ABO incompatibility. Small sized study population 
was another limitation of this study.
CONCLUSION
The present study concludes that in high flow resource constraint 
maternity hospitals, where maximum numbers of deliveries 
take place, all the babies who develop clinical jaundice must 
be checked for the mother’s blood group. All babies born to O 
positive mother developing clinical jaundice should be evaluated 
for blood group as soon as possible to identify the high-risk 
neonates developing jaundice and/or anemia due to ABO 
incompatibility. We also conclude that the blood group (A/B) has 
no effect on the parameters that may influence the outcome of 
ABO incompatibility.
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